Australian Researcher Working on Immune-Based Therapy

A researcher at the Royal Adelaide Hospital in Melbourne has entered into an agreement with an Australian biotech company, Virax Holdings, to further develop leads for an immune-based therapy to treat advanced prostate cancer.

Dr. Michael Brown, a medical oncologist currently conducting a prostate cancer study funded by a U.S. Defense Department award, said he will work on a vaccine that uses Virax's Co-X-Gene™ in FPV (fowlpox virus) vector.

"The most important current, unmet need in the management of prostate cancer is therapy that is effective against hormone-refractory, metastatic disease," said Brown.

A short list of leads has been selected for the prostate cancer development program and these will undergo testing to determine the ultimate candidate to bring into clinical trials, he added.

Other Sources: Virax